SAFE FERTILITY GROUP PUBLIC COMPANY LIMITED
5.20
THB
-0.05
(-0.95%)
ISIN
THB695010009
Return %
Stock
S&P 500
1Y
-28.77
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
THB
•
in mil. unless spec.Working Capital
THB
•
in mil. unless spec.Growth Rates
THB
•
in mil. unless spec.Quarterly Revenue
THB
•
in mil. unless spec.Quarterly Earnings Per Share
THB
•
in mil. unless spec.Quarterly Dividends Per Share
THB
•
in mil. unless spec.Company Description
- CEO
- Wiwat Quangkananurug
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- Bangkok Thailand
- IPO Date
- Nov 2, 2023
- Website
- safefertilitygroup.com
- Similar Companies
- Business
- Safe Fertility Group Public Company Limited is a Thailand-based healthcare provider specializing in assisted reproductive technology (ART), clinical genetic testing, and integrated wellness services. Founded in 2007 and headquartered in Bangkok, Thailand, the company operates specialized fertility clinics and diagnostic laboratories that cater to both domestic and international patients across key metropolitan and medical tourism destinations, including Bangkok (Gaysorn Amarin flagship and Ramindra), Phuket, Khon Kaen, and Sriracha. The group is the first fertility clinic operator in Thailand to receive international accreditation from the Reproductive Technology Accreditation Committee (RTAC) of Australia and New Zealand. The company operates through three principal business divisions: Infertility Treatment and Clinical Services, Genetic Laboratory and Diagnostics, and Aesthetic Wellness. Its core products and service offerings comprise: assisted reproductive technologies and fertility treatments, including in vitro fertilization (IVF); intracytoplasmic sperm injection (ICSI); intrauterine insemination (IUI); intracytoplasmic morphologically-selected sperm injection (IMSI); testicular sperm extraction (TESE) and percutaneous epididymal sperm aspiration (PESA); magnetic-activated cell sorting (MACS); time-lapse embryo incubation and monitoring through EmbryoScope technology; and vitrification and cryopreservation of oocytes, sperm, and embryos; comprehensive genetic testing and laboratory services conducted primarily through its specialized subsidiary, Next Generation Genomic Co., Ltd. (NGG Thailand), including preimplantation genetic testing for aneuploidies (PGT-A), monogenic defects (PGT-M), and structural chromosomal rearrangements (PGT-SR); non-invasive prenatal testing (NIPT); next-generation sequencing (NGS); carrier screening; and molecular diagnostic testing for external hospitals and clinics; and supportive wellness and cosmetic dermatology services operated through Safe Wellness Co., Ltd., encompassing reproductive acupuncture, anti-aging treatments, and aesthetic skin procedures. In recent developments, Safe Fertility Group completed its initial public offering and began trading on the Stock Exchange of Thailand under the ticker symbol SAFE in November 2023, utilizing proceeds to expand clinical footprints and upgrade laboratory infrastructure. The company entered into a strategic collaboration with Juno Genetics to implement PGTseq-A targeted next-generation sequencing technology, enhancing chromosomal screening accuracy and clinical pregnancy success rates. In addition, the group has actively expanded business-to-business genetic testing partnerships with domestic and regional healthcare institutions while broadening its medical tourism marketing channels to capture growing demand from cross-border patients across Asia.